Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Pharming Group N.V. PHAR

Set alert

Price alert · PHAR

All alert types
12.74 USD +0.07 +0.55%

As of Nov 3, 12:28 PM ET

Bid
12.35 × 1
Ask
12.71 × 1
12.45 Day range 12.98
9.11 52-week range 21.34
YTD
-27.90%
1 year
-4.35%
Open
12.69
Prev close
12.67
Mkt cap
901.71M
Vol
7.26K
Avg vol
24.16K
EPS
0.32
P/E
39.81
Div yield
0.00%
More statistics
Low
12.45
High
12.98
Forward P/E
216.49
Beta
0.09
Short ratio
0.38
Inst. own
0.14%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
13.57
200-d avg
15.63
1y target
34.35

3M chart

Chart tools
Interval
1m5m15m30m

Signals (19)
NameDateAgo
RSI: OverboughtOct 30, 20264 days ago
RSI: OverboughtOct 28, 20266 days ago
SMA: BullishOct 23, 20261 week ago
SMA: BullishOct 22, 20261 week ago
MACD: Buy SignalOct 20, 20262 weeks ago
MACD: Sell SignalOct 19, 20262 weeks ago
MACD: Buy SignalOct 15, 20262 weeks ago
MACD: Sell SignalSep 24, 20261 month ago
MACD: Buy SignalSep 22, 20261 month ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BullishSep 8, 20261 month ago
MACD: Buy SignalSep 8, 20261 month ago
MACD: Sell SignalSep 4, 20262 months ago
MACD: Buy SignalSep 3, 20262 months ago
MACD: Sell SignalSep 2, 20262 months ago
SMA: BearishAug 27, 20262 months ago
SMA: BullishAug 26, 20262 months ago
MACD: Buy SignalAug 11, 20262 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 34.35 +169.6% upside
Target (low)
23.40
Target (mean)
34.35
Target (high)
40.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 4
  • 1 month ago 4
  • 2 months ago 4
  • 3 months ago 4

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PHAR analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.0630.01 – 0.150.006+950.0%101.28M+8.6%3
Next quarter0.0820.02 – 0.200.01+720.0%109.72M+12.8%3
Current year0.230330.05 – 0.570.04+475.8%403.52M+7.3%3
Next year0.06550.05 – 0.0810.23033-71.6%447.80M+11.0%2

Upgrades and downgrades

The latest rating changes

PHAR analyst upgrades and downgrades
DateFirmActionFromTo
Apr 10, 2026Canaccord GenuityInitiated—Buy
Mar 24, 2026HC Wainwright & Co.ReiteratedBuyBuy
Mar 13, 2026OppenheimerReiteratedOutperformOutperform
Mar 21, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 20, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 14, 2025OppenheimerMaintainedOutperformOutperform
Mar 14, 2025HC Wainwright & Co.ReiteratedBuyBuy
Dec 17, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 11, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 9, 2024JefferiesInitiated—Buy
Oct 28, 2024OppenheimerMaintainedOutperformOutperform
Oct 24, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 10, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 26, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 1, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 31, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 14, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 3, 2023HC Wainwright & Co.Reiterated—Buy
Mar 28, 2023OppenheimerMaintained—Outperform
Mar 27, 2023HC Wainwright & Co.Reiterated—Buy
Feb 22, 2023HC Wainwright & Co.Reiterated—Buy
Feb 16, 2023HC Wainwright & Co.Reiterated—Buy